Navigation Links
Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
Date:8/11/2009

CHICAGO, Aug. 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The net loss allocable to common shareholders for the three months ended June 30, 2009 was $2.6 million or ($0.06) per share compared to a net loss allocable to common shareholders of $3.4 million or ($0.09) per share for the three months ended June 30, 2008. The decrease in the net loss is due to decreased costs involved in the clinical development of the Company's lead compound, Restanza(TM) (cethromycin).

The Company ended the second quarter of 2009 with cash and cash equivalents totaling $1.0 million. Cash used during the quarter was approximately $2.9 million.

"Advanced Life Sciences today is focused on continuing to pursue approval for Restanza in community acquired pneumonia or CAP and complying with the recommendations by the FDA concerning next steps that can lead to a registration pathway," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "Based on the agency's recent communication with the Company, we anticipate that an additional well-controlled clinical study designed to demonstrate efficacy in a more severe CAP population will likely be required for the approval of Restanza. We intend to work closely with the agency to design and establish a protocol under a Special Protocol Assessment. We are working on these clinical plans with Wyeth, our development and commercialization partner in the Asia
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
2. Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast
3. Next Safety Releases Advanced Respirator for Infectious Diseases
4. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
5. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
6. Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada
7. Unexpectedly long-range effects in advanced magnetic devices
8. UCF teams advanced nerve cell system could help cure diabetic neuropathy, related diseases
9. Advanced Life Sciences Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study
10. Visage Imaging to Provide Visage(R) CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants
11. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Global Stem Cells Group today ... annual gathering of aesthetic medicine experts and innovators. GSCG ... introduce the company’s brand new training course that combines ... techniques. , The course is designed to address ... field, including facial aging caused by volume loss. ...
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... today announced that it has received approval from ... of 5,126,044 outstanding common share purchase warrants ("the ... connection with the Company,s May 2013 private placement ...
(Date:4/17/2015)... Global Stem Cells Group has announced ... April 27 - 29, 2015 in Boston. This world-class ... of stem cell research including applications, biology, medicine, regulations, ... , The conference will address recent developments in ... in stem cell therapies, regenerative medicine, tissue engineering, stem ...
Breaking Biology Technology:Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3
... 2 or 3 patients achieve undetectable HCV RNA levels, following 4 weeks of treatment with ... ... with Pegasys ... plus Copegus -, PRINCETON, N.J., Sept. 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces ...
... Whalen as Solutions Director. , ... ... [Symphony Management Consulting] announced that it has appointed A.J. Whalen ... from Wellesley Information Services (WIS) where he was responsible for ...
... helps visitors to electronica 2008 in Munich and covers topics such ... sources of pre-show information useful in planning a trip, online registration ... an extensive list of web links to travel, hotel, city and ... ...
Cached Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Immediate Release,Wednesday, October 28, 2009 Contact:,Robin Mackar, NIEHS,(919) ... Bisph Researchers studying the health effects of the chemical ... an integrated research initiative to produce data that will ... health effects. Researchers who just received funds ...
... 2009) Paved parking lots and driveways make our lives ... to reach underground water sources and alter the natural flow ... Agency today announced a study that will investigate ways to ... how water filters back into the ground. EPA is testing ...
... identified wheat and barley lines resistant to Crown Rot ... million in lost yield every year. Crown Rot, which ... caused by the fungus Fusarium . Dr Chunji ... using sophisticated screening methods to scan over 2400 wheat lines ...
Cached Biology News:NIEHS awards Recovery Act funds to address bisphenol A research gaps 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 3NIEHS awards Recovery Act funds to address bisphenol A research gaps 4NIEHS awards Recovery Act funds to address bisphenol A research gaps 5NIEHS awards Recovery Act funds to address bisphenol A research gaps 6NIEHS awards Recovery Act funds to address bisphenol A research gaps 7NIEHS awards Recovery Act funds to address bisphenol A research gaps 8EPA's new green parking lot allows scientists to study permeable surfaces that may help the environment 2
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in cell ... Purity: ≥98% by TLC. Soluble in DMSO ... of a 10 mM stock in DMSO is recommended. ... H 2 O with rapid mixing (e.g. 10 μl ...
Biology Products: